Giuseppe Minniti is an expert in Oncology at Istituto Neurologico Mediterraneo (Italy). As of October 2026, ScienceLeadR ranks Giuseppe Minniti in the top 1% of experts worldwide for Nervous System Neoplasms and Glioma, and in the top 1% of experts in Italy for Brain Neoplasms. Giuseppe Minniti has authored 427 publications, the most recent in 2026, and is an investigator in 5 clinical trials, 5 of them ongoing. SLR score: 1,449 (community average: 125). How the SLR is computed.

LeadR Profile

1 449 ScienceLeadR Reputation 1449
Network Map

Oncology

Subspecialties: Neurology - Radiotherapy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1994 - 2026

Source: PubMed

Sapienza University of Rome

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 427

Citations

Citations: 16 977 1st author: 90 Last author: 55 Unique author: 2


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Reirradiation of recurrent brain tumors: a review by the ESTRO CNS Focus Group.
PMID 42835612 — brain neoplasms, safety, focus groups, brain, neoplasms, re-irradiation, therapeutics
Clin Transl Radiat Oncol20260
Anatomical-molecular interaction in glioblastoma: subventricular zone involvement and MGMT-related survival benefit.
PMID 42778788 — radiotherapy, promoter regions, genetic, glioblastoma, medical oncology
Strahlenther Onkol20260
Multidisciplinary recommendations for routine follow-up of isocitrate dehydrogenase‑mutant glioma in 2026: Adapting clinical practice to the molecular era.
PMID 42750913 — radiotherapy, glioma, growth, oxidoreductases, isocitrate dehydrogenase, neoplasms, drug therapy, therapeutics, chemotherapy
Neurooncol Pract20260
Four Synchronous Myxomas Unmasking Carney Complex: When to Think About Carney Complex?
PMID 42690208 — carney complex, mitral valve, stroke, protein kinases, neoplasms, myxoma, echocardiography, diagnosis, wounds and injuries
JACC Case Rep20260
ESTRO, ESNR and EORTC consensus-based definition for MRI abnormalities after radiotherapy for intracranial central nervous system tumours.
PMID 42623110 — delphi technique, radiotherapy, brain neoplasms, clinical decision-making, central nervous system, nervous system, medical oncology
Neuro Oncol20260

Clinical Studies 5

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 2 2
Phase 3 2
N/A 1

By status:

Recruiting 5

By type:

Interventional 5

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 0
multicentric5to9 1
multicentricup10 4

Main Topics

Ongoing Clinical Trials

5 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
APalutamide and stEReotactic body radiation therapy for low burden metastatic hormone senSItive prostate cancer a rANdomized trial PERSIAN
2022-501894-37-00 — radiotherapy, androgens, neoplasms, prostate, hormones, prostatic neoplasms, therapeutics
Phase 2Recruiting2023
Regorafenib for Recurrent Meningioma (MIRAGE Trial)
NCT06275919 — cells, pharmaceutical preparations, neoplasms, disease progression, tablets, meningioma
Phase 2Recruiting2024
Lomustine With and Without Reirradiation for First Progression of Glioblastoma a Randomized Phase III Study
NCT05904119 — radiotherapy, administration, oral, lomustine, re-irradiation, glioblastoma, therapeutics
Phase 3Recruiting2024
Preoperative vs Postoperative Hypofractionated Radiosurgery for Patients With Large Brain Metastases
NCT05545007 — brain neoplasms, radiosurgery, brain, neoplasms, neoplasm metastasis, tissues, wounds and injuries
N/ARecruiting2023
Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non small Cell Lung Cancer
NCT05522660 — radiotherapy, cells, lung, radiosurgery, melanoma, brain, neoplasms, carcinoma, non-small-cell lung, drug therapy, immunotherapy, immune checkpoint inhibitors, lung neoplasms, neoplasm metastasis, small cell lung carcinoma, therapeutics, mutation, chemotherapy, carcinoma
Phase 3Recruiting2022

LeadR Networks

Main global connection map